Cero Therapeutics Holdings, Inc. cash flow statement CEROW

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Cero Therapeutics Holdings, Inc. used $7.9 million of cash from operations.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2023
Dec 31, 2023
Q3 FY2023
Sep 30, 2023
Q2 FY2023
Jun 30, 2023
Q1 FY2023
Mar 31, 2023
Q4 FY2022
Dec 31, 2022
Q3 FY2022
Sep 30, 2022
Operating
Depreciation and amortization
—
0
-23.3%
—
—
—
—
0
—
—
Stock-based compensation
—
3
—
—
—
—
—
—
—
Operating cash flow
—
-8
3
-0
+50.0%
-0
-46.9%
-1
-273.1%
-0
+35.8%
-0
-0
Investing
Investing cash flow
—
—
—
-14
-107.6%
6
+4327.4%
0
-0
181
0
Financing
Short-term debt issued
—
2
2
—
—
—
—
—
—
Dividends paid
—
—
0
—
—
—
—
—
—
Stock buybacks
—
—
—
28
6
—
—
—
—
Financing cash flow
—
4
—
-28
-5
1
—
—
—
Change in cash
Net change in cash
—
—
—
-42
-200.1%
0
+130.0%
-0
+86.6%
-0
42
-0
Shareholder returns
Returned to shareholders
—
—
0
28
6
—
—
—
—
Ratios
Cash conversion
—
—
—
—
—
—
—
—
-2.06x
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CERO (OTC), CEROW (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1870404
Former names
CERO THERAPEUTICS HOLDINGS, INC. (until Oct 7, 2026); PHOENIX BIOTECH ACQUISITION CORP. (until Feb 14, 2024)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.